Abstract:Background. A large number of cancer-related deaths in the world can be attributed to liver hepatocellular carcinoma (LIHC). The purpose of this study is to explore protein tyrosine phosphatase type IV A member 3 (PTP4A3/PRL-3) as a new and reliable biomarker to predict the prognosis of LIHC and determine the potential therapeutic targets or drugs that can be used for treating LIHC. Methods. We included three LIHC datasets with clinical information and expression profiles from public databases. The expression level of PTP4A3 was analyzed, and based on the results, the samples were divided into high- and low-expression groups. The Kaplan–Meier survival analysis method was used to determine the relationship between PTP4A3 and prognosis. The enrichment differences among the functional pathways associated with the high- and low-expression groups were determined using the gene set enrichment analysis (GSEA) method. Five methods were used to determine the differences among the tumor microenvironment in the low- and high-expression groups. The sensitivity of the low- and high-expression groups toward different drug treatment methods was predicted by analyzing the Tumor Immune Dysfunction and Exclusion (TIDE) scores and determining the biochemical half-maximal inhibitory concentration (IC50). Results. The expression levels of the LIHC and adjacent samples were analyzed, and it was observed that the expression level of PTP4A3 in tumor tissue was significantly higher than the expression level of the same gene in the adjacent samples. It was also inferred that it might be a cancer-promoting gene. It was concluded that high-expression results in a significantly poor prognosis. The high-expression group was significantly enriched in the tumor-related pathways, such as the PI3K-AKT signaling pathway. In addition, the results obtained by conducting immune infiltration analysis revealed a significant positive correlation between some immune scores and the gene PTP4A3. The drug KIN001−135 and gene PTP4A3 were also found to correlate positively with each other. CP466722, Pyrimethamine, AKT inhibitor VIII, Embelin, Cisplatin, QS11, Bexarotene, and Midostaurin negatively correlated with PTP4A3 associated with the three datasets. Moreover, the drugs Cisplatin, QS11, Midostaurin, and CP466722 were more sensitive toward the high-expression group than the low PTP4A3 expression group. Significant differences were observed in these cases. Conclusion. PTP4A3/PRL-3 is potentially associated with the progression, metastasis, and invasion of LIHC. The prognosis of LIHC patients is negatively impacted by the high-expression levels of the gene. The results indicate that PTP4A3/PRL-3 is an important prognostic factor for LIHC and is a new potential prognostic detection target. The discovery of the 8 drugs that were negatively associated with PTP4A3 provided a new direction that can be developed in the future for the treatment of LIHC.

Targeting PRL phosphatases in hematological malignancies

Protein Tyrosine Phosphatase PRL-3: A Key Player in Cancer Signaling

Combination of Theoretical Analysis and Experiments: Exploring the Role of PLA2G7 in Human Cancers, Including Renal Cancer

Expression and Clinical Significance of Phospholipase D1 in De Novo Acute Myeloid Leukemia

PRL1 and PRL3 promote macropinocytosis via its lipid phosphatase activity

Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP

Tumor Metastasis-Associated Molecule PRL-3:structure,function and Possibility As the Target of Anti-Cancer Drugs

Phospholipase D as a key modulator of cancer progression

Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.

Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion.

Roles of protein tyrosine phosphatase SHP2 in lung cancer

Phosphatase Regenerating Liver 3 Participates in Integrinβ1/FAK-Src/MAPK Signaling Pathway and Contributes to the Regulation of Malignant Behaviors in Hepatocellular Carcinoma Cells

Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.

Phosphatase Activity, Trimerization, and the C-terminal Polybasic Region Are All Required for PRL1-mediated Cell Growth and Migration.

Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases

Phosphatase of Regenerating Liver-3 (PRL-3) is Associated with Metastasis and Poor Prognosis in Gastric Carcinoma

Phosphatase of Regenerating Liver-3 Localizes to Cyto-Membrane and is Required for B16F1 Melanoma Cell Metastasis in Vitro and in Vivo

Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia

Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma

Phosphatase of Regenerating Liver-3 Directly Interacts with Integrin Β1 and Regulates Its Phosphorylation at Tyrosine 783

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond